Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures
Diabetes Care · 2026
DOI: 10.2337/dc26-0567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Christoph Strohhofer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, University Heart Center Graz, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Fasting, Prediabetic State, Hydroxybutyrates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Medical University of Graz, Austrian Science Fund (FWF).
Abstract (Originalsprache)
OBJECTIVE We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. RESEARCH DESIGN AND METHODS Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c <39 mmol/mol (5.7%). RESULTS Among 772 individuals, 2-HB increased from normoglycemia (39.0 µmol/L) to prediabetes (51.9 µmol/L) and type 2 diabetes (57.0 µmol/L). In 534 individuals with normal FPG and HbA1c, 2-HB yielded the area under the receiver operating characteristic curve of 0.79 for postprandial dysglycemia (2-h glucose >140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). CONCLUSIONS Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, University Heart Center Graz, Medical University of Graz, Graz, Austria.
- Cluster of Excellence MetAGE, Graz, Austria.
- Core Facility Computational Bioanalytics, Medical University of Graz, Graz, Austria.
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Endocrinology Lab Platform, Division of Endocrinology and Diabetology, Department of Internal Medicine and Department of Gynecology and Obstetrics, Medical University of Graz, Graz, Austria.
- DirectSens GmbH, Vienna, Austria.
ORCID-Profile: Christoph Strohhofer, Harald Sourij, Thomas R Pieber
Förderung
- Medical University of Graz
- Austrian Science Fund (FWF)
Zitieren
APA
Strohhofer, C., Eberhard, K., Obermayer-Pietsch, B., Stadler, D., Herzog, P., Schwegel, N., Santner, V., Niedrist, T., Herrmann, M., von Lewinski, D., Zirlik, A., Sourij, H., Verheyen, N., & Pieber, T. R. (2026). Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures. Diabetes Care. https://doi.org/10.2337/dc26-0567
Vancouver
Strohhofer C, Eberhard K, Obermayer-Pietsch B, Stadler D, Herzog P, Schwegel N, et al. Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures. Diabetes Care. 2026. doi:10.2337/dc26-0567
BibTeX
@article{Strohhofer2026,
author = {Strohhofer, Christoph and Eberhard, Katharina and Obermayer-Pietsch, Barbara and Stadler, David and Herzog, Peter and Schwegel, Nora and Santner, Viktoria and Niedrist, Tobias and Herrmann, Markus and von Lewinski, Dirk and Zirlik, Andreas and Sourij, Harald and Verheyen, Nicolas and Pieber, Thomas R},
title = {Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc26-0567}
}
EUVIMED